OTX015 + azacitidine

**OTX015 + azacitidine** is an investigational combination therapy consisting of the small-molecule BET inhibitor OTX015 (also known as MK-8628) and the hypomethylating agent azacitidine. OTX015 inhibits the bromodomain and extraterminal (BET) proteins—primarily BRD2, BRD3, and BRD4—which results in the suppression of oncogenic transcription factors such as c-MYC, leading to cell cycle arrest and apoptosis in leukemic cells. Azacitidine is a DNA methyltransferase inhibitor that restores normal function to tumor suppressor genes by hypomethylation, and is widely used in the treatment of myelodysplastic syndromes and acute myeloid leukemia (AML). Preclinical and early clinical evidence shows a synergistic anti-leukemic effect when OTX015 is combined with azacitidine, particularly in AML cell lines, enhancing cell growth inhibition and apoptosis beyond either agent alone. The combination primarily targets patient populations with newly diagnosed or relapsed/refractory AML who are not candidates for intensive induction chemotherapy[1][2][3][4].